|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/28/24 Acadia Pharmaceuticals Inc. 10-K 12/31/23 88:14M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 2.81M
3: EX-10.13 Material Contract HTML 40K
4: EX-10.17 Material Contract HTML 610K
5: EX-10.18 Material Contract HTML 32K
6: EX-10.19 Material Contract HTML 31K
7: EX-10.20 Material Contract HTML 44K
8: EX-10.35 Material Contract HTML 355K
9: EX-10.36 Material Contract HTML 289K
10: EX-10.37 Material Contract HTML 63K
11: EX-10.38 Material Contract HTML 366K
2: EX-10.5 Material Contract HTML 97K
12: EX-21.1 Subsidiaries List HTML 26K
13: EX-23.1 Consent of Expert or Counsel HTML 28K
18: EX-97.1 Clawback Policy re: Recovery of Erroneously HTML 39K
Awarded Compensation
14: EX-31.1 Certification -- §302 - SOA'02 HTML 30K
15: EX-31.2 Certification -- §302 - SOA'02 HTML 30K
16: EX-32.1 Certification -- §906 - SOA'02 HTML 27K
17: EX-32.2 Certification -- §906 - SOA'02 HTML 27K
20: R1 Document and Entity Information HTML 99K
21: R2 Consolidated Balance Sheets HTML 126K
22: R3 Consolidated Balance Sheets (Parenthetical) HTML 45K
23: R4 Consolidated Statements of Operations HTML 94K
24: R5 Consolidated Statements of Comprehensive Loss HTML 48K
25: R6 Consolidated Statements of Cash Flows HTML 120K
26: R7 Consolidated Statements of Stockholders' Equity HTML 77K
27: R8 Pay vs Performance Disclosure HTML 38K
28: R9 Insider Trading Arrangements HTML 46K
29: R10 Organization and Business HTML 29K
30: R11 Summary of Significant Accounting Policies HTML 185K
31: R12 Investments HTML 151K
32: R13 Fair Value Measurements HTML 132K
33: R14 Balance Sheet Details HTML 91K
34: R15 Stockholders' Equity HTML 124K
35: R16 401(k) Plan HTML 33K
36: R17 Income Taxes HTML 199K
37: R18 Commitments and Contingencies HTML 64K
38: R19 Leases HTML 92K
39: R20 Selected Quarterly Financial Data (Unaudited) HTML 89K
40: R21 SCHEDULE II - Valuation and Qualifying Accounts HTML 54K
41: R22 Summary of Significant Accounting Policies HTML 239K
(Policies)
42: R23 Summary of Significant Accounting Policies HTML 131K
(Tables)
43: R24 Investments (Tables) HTML 148K
44: R25 Fair Value Measurements (Tables) HTML 130K
45: R26 Balance Sheet Details (Tables) HTML 93K
46: R27 Stockholders' Equity (Tables) HTML 81K
47: R28 Income Taxes (Tables) HTML 193K
48: R29 Leases (Tables) HTML 84K
49: R30 Selected Quarterly Financial Data (Unaudited) HTML 88K
(Tables)
50: R31 Summary of Significant Accounting Policies - HTML 35K
Schedule of Reconciliation of Cash, Cash
Equivalents and Restricted Cash (Detail)
51: R32 Summary of Significant Accounting Policies - HTML 76K
Additional Information (Detail)
52: R33 Summary of Significant Accounting Policies - HTML 36K
Schedule of Estimated Useful Lives by Major Asset
Category (Detail)
53: R34 Summary of Significant Accounting Policies - HTML 37K
Schedule of Revenues consist of product sales to
customers (Details)
54: R35 Summary of Significant Accounting Policies - HTML 36K
Weighted-Average Assumptions Used to Estimate Fair
Value of Employee Stock Options (Detail)
55: R36 Summary of Significant Accounting Policies - HTML 44K
Weighted-Average Assumptions Used to Estimate Fair
Value of Employee Stock Purchase Plan Rights
(Detail)
56: R37 Summary of Significant Accounting Policies - HTML 35K
Summary of Stock-based Compensation Expense
Included in Statements of Operations (Detail)
57: R38 Investments - Carrying Value and Amortized Cost of HTML 58K
Company's Investments Summarized by Major Security
Type (Detail)
58: R39 Investments - Additional Information (Detail) HTML 35K
59: R40 Investments - Summary of Gross Unrealized Losses HTML 53K
and Fair Value of Available-For-Sale Investment
Securities in Unrealized Loss Position (Detail)
60: R41 Fair Value Measurements - Fair Value Measurements HTML 62K
of Cash Equivalents, Available-For-Sale Investment
Securities and Equity Securities (Detail)
61: R42 Fair value measurement - Changes in estimated fair HTML 34K
value of contingent cash award (Details)
62: R43 Balance Sheet Details - Schedule of Inventory HTML 38K
(Detail)
63: R44 Balance Sheet Details - Property and Equipment, HTML 40K
Net (Detail)
64: R45 Balance Sheet Details - Additional Information HTML 29K
(Detail)
65: R46 Balance Sheet Details - Schedule of Accrued HTML 42K
Liabilities (Detail)
66: R47 Stockholders' Equity - Additional Information HTML 141K
(Detail)
67: R48 Summary of Company's Stock Option Activity HTML 68K
(Detail)
68: R49 Summary of Company's RSU Activity (Detail) HTML 51K
69: R50 401 (k) Plan - Additional Information (Detail) HTML 33K
70: R51 Income Taxes - Summary of Domestic and Foreign HTML 34K
Pre-tax Loss (Detail)
71: R52 Income Taxes - Schedule of Income Tax Provision HTML 40K
(Details)
72: R53 Income Taxes - Additional Information (Detail) HTML 62K
73: R54 Income Taxes - Components of Deferred Tax Assets HTML 61K
(Detail)
74: R55 Income Taxes - Reconciliation of Income Taxes to HTML 60K
Amount Computed by Applying Statutory Federal
Income Tax Rate to Pretax Loss (Detail)
75: R56 Income Taxes - Unrecognized Tax Benefits (Detail) HTML 34K
76: R57 Commitments and Contingencies - Additional HTML 95K
Information (Detail)
77: R58 Leases - Additional Information (Detail) HTML 88K
78: R59 Leases - Summary of Operating Lease Costs (Detail) HTML 31K
79: R60 Leases - Supplemental Cash Flow Information HTML 29K
Related to the Company's Leases (Detail)
80: R61 Leases - Summary of Balance Sheet Classification HTML 33K
of Lease Liabilities (Detail)
81: R62 Leases - Summary of Maturities of Lease HTML 46K
Liabilities (Detail)
82: R63 Selected Quarterly Financial Data (Unaudited) - HTML 72K
Selected Quarterly Financial Data (Detail)
83: R64 SCHEDULE II - Valuation and Qualifying Accounts HTML 37K
(Detail)
85: XML IDEA XML File -- Filing Summary XML 147K
88: XML XBRL Instance -- acad-20231231_htm XML 2.93M
84: EXCEL IDEA Workbook of Financial Report Info XLSX 167K
19: EX-101.SCH XBRL Taxonomy Extension Schema With Embedded XSD 3.61M
Linkbases Document -- acad-20231231
86: JSON XBRL Instance as JSON Data -- MetaLinks 566± 903K
87: ZIP XBRL Zipped Folder -- 0000950170-24-021473-xbrl Zip 988K
| EX-31.1 |
EXHIBIT 31.1
CERTIFICATION
Pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934,
as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, Stephen R. Davis, certify that:
1. I have reviewed this annual report on Form 10-K for the year ended December 31, 2023 of Acadia Pharmaceuticals Inc.
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: February 27, 2024 |
|
/s/ STEPHEN R. DAVIS |
|
|
Stephen R. Davis |
|
|
Chief Executive Officer |
|
|
(Registrant’s Principal Executive Officer) |
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed as of: | 2/28/24 | |||
| Filed on: | 2/27/24 | 4, 8-K | ||
| For Period end: | 12/31/23 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/09/24 Acadia Pharmaceuticals Inc. 10-Q 3/31/24 62:7.2M Donnelley … Solutions/FA |